03 Oct 2008 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Oct 2008
Therapeutic Registrations by SWOG Institutions Only (Txca=Y)
76% of Calendar Year is Past
Projected 12 Month
2008 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2008 (Decrease) Last (Decrease)
Committee 2003 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BRAIN 70 0 0% 0 <70> 0 <70>
BREAST 728 1188 163% 1565 837 1514 786
ERLYTX 0 11 14 14 17 17
GI 121 463 383% 610 489 635 514
GU 412 420 102% 553 141 518 106
GYN 120 0 0% 0 <120> 0 <120>
HN 48 1 2% 1 <47> 11 <37>
IMMUNO 5 0 0% 0 <5> 0 <5>
LEUK 86 174 202% 229 143 232 146
LUNG 416 147 35% 194 <222> 179 <237>
LYMPH 149 172 115% 227 78 214 65
MELAN 54 75 139% 99 45 111 57
MMYEL 44 22 50% 29 <15> 26 <18>
SARC 9 0 0% 0 <9> 0 <9>
------------ ---------- --------- ---------- --------- ----------
2262 2673 3522 1260 3457 1195
03 Oct 2008 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Oct 2008
Non-Therapeutic Registrations by SWOG Institutions Only
76% of Calendar Year is Past
Projected 12 Month
2008 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2008 (Decrease) Last (Decrease)
Committee 2003 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 26 24 92% 32 6 39 13
CC 0 2 3 3 2 2
GI 1 0 0% 0 <1> 0 <1>
GU 225 0 0% 0 <225> 0 <225>
GYN 3 0 0% 0 <3> 0 <3>
HN 27 0 0% 0 <27> 0 <27>
LEUK 142 320 225% 422 280 433 291
LUNG 242 57 24% 75 <167> 80 <162>
LYMPH 29 60 207% 79 50 80 51
MELAN 9 0 0% 0 <9> 0 <9>
MMYEL 31 50 161% 66 35 65 34
------------ ---------- --------- ---------- --------- ----------
735 513 676 <59> 699 <36>
03 Oct 2008 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Oct 2008
All Initial Registrations by SWOG Institutions
76% of Calendar Year is Past
Projected 12 Month
2008 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2008 (Decrease) Last (Decrease)
Committee 2003 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BRAIN 70 0 0% 0 <70> 0 <70>
BREAST 754 1212 161% 1597 843 1553 799
CC 0 2 3 3 2 2
ERLYTX 0 11 14 14 17 17
GI 122 463 380% 610 488 635 513
GU 637 420 66% 553 <84> 518 <119>
GYN 123 0 0% 0 <123> 0 <123>
HN 75 1 1% 1 <74> 11 <64>
IMMUNO 5 0 0% 0 <5> 0 <5>
LEUK 228 494 217% 651 423 665 437
LUNG 658 204 31% 269 <389> 259 <399>
LYMPH 178 232 130% 306 128 294 116
MELAN 63 75 119% 99 36 111 48
MMYEL 75 72 96% 95 20 91 16
SARC 9 0 0% 0 <9> 0 <9>
------------ ---------- --------- ---------- --------- ----------
2997 3186 4198 1201 4156 1159
03 Oct 2008 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Oct 2008
Initial Registrations to Cancer Control Studies
76% of Calendar Year is Past
Projected 12 Month
2007 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2007 (Decrease) Last (Decrease)
Committee 2006 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 26 110 423% 145 119 125 99
CC 0 2 3 3 2 2
GI 29 0 0% 0 <29> 0 <29>
GU 428 191 45% 252 <176> 255 <173>
HN 14 0 0% 0 <14> 0 <14>
LUNG 84 70 83% 92 8 94 10
LYMPH 9 2 22% 3 <6> 4 <5>
------------ ---------- --------- ---------- --------- ----------
590 375 494 <96> 480 <110>
03 OCT 2008 Southwest Oncology Group Open and Temporarily Closed Studies
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.
Monthly Date of
Stat Open Months Total Accrual Accrual Expected Closure or
Comm. Phase Study Center Date Open Regs Goal Rate Temporary Closure
------ ------ ------------------------------------ -------- ---------- ------- ------ ------- -------- --------------------
BREAST BIOL S0307A Breast, Bone Quality SWOG 01-OCT-08 0 0 90
II S0622 Breast, Adv, 2 sched Dasatinib SWOG 15-MAR-07 18 32 80 2.2 Aug-2010
III C40101 Breast, Adj, Node neg, AC vs CALGB 15-MAY-02 683 3.2
T
JMA20 Breast, Early, Regional RT NCIC 03-OCT-02 8 .0
IBC24-02 Ovar Ftn suppress/premeno IBCSG 04-AUG-03 142 3.3
S0230 Breast,Adj,Chemo +/- Goserelin SWOG 01-OCT-03 60 141 458 5.5 Jul-2013
S0221 Breast,Adj,N+,ACvAC+G/Pac q1v2 SWOG 01-NOV-03 59 2213 3250 24.0 May-2012
S0226 Brst,Adv,Anastrozole +/- Fulv SWOG 01-APR-04 54 550 690 15.8 Jun-2009
JMA17R Breast,Adj,Letrozole v Placeb NCIC 15-NOV-04 46 188 1800 8.3
o
B39 Stg 0-2, whole vs partial RT NSABP 22-MAR-05 14 .2
S0307 Breast, Adj, Bisphosphonates SWOG 15-NOV-05 34 1958 4500 130.0 May-2010
N0434 JMA27 Companion Study NCCTG 08-DEC-05 100 1.7
JMA27B 5yr Adj Anast vs Exemestrane NCIC 24-APR-06 94 .5
PACCT-1 Assess of Ca Clinical Tests ECOG 24-APR-06 814 40.3
C40302 Endocrine +/1 Inhibition CALGB 22-SEP-06 10 .7
S0500 Brst,Adv,CTC,mntain v chnge tx SWOG 01-OCT-06 24 173 500 8.5 Dec-2011
E1105 Adv, Trastuzumab +/- Bev ECOG 21-NOV-07 2 .0
N063D ALTTO NCCTG 15-FEB-08 1 .2
N0733 Her2+, Cap + Lap +/- IMC-A12 NCCTG 30-JUL-08 0
ERLYTX I S0528 Adv.Solid Tumors, Lapat.+Ever. SWOG 01-SEP-06 25 30 48 1.2 Jan-2010
GI I-II S0727 Panc,Met,Gem/Erlotinib/IMC-A12 SWOG 01-MAR-08 4 118 Sep-2008 Temp Close
III C80101 GI, Adj, 5-FU/Lv vs. ECF CALGB 19-DEC-02 95 1.7
N0147 Colon,Stg III,resection+chemo NCCTG 10-FEB-04 504 9.3
R04 Rectum, Capecitabine vs 5FU NSABP 09-AUG-04 24 1.2
E5202 Stg2,5FU/Leuc/Oxal +/- Bev ECOG 08-AUG-05 223 9.0
C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux CALGB 26-SEP-05 422 2289 7.2
E5204 Rectal, 5FU,Oxal,Leuc +/- Bev ECOG 08-MAR-06 65 2.8
S0600 COLREC,Met,Chemo,Cetuximab/Bev SWOG 15-JUN-07 51 1260 Jun-2008 Temp Close
S0518 Carcinoid,Adv,Octreo/Alpha/Bev SWOG 01-DEC-07 10 51 283 7.7 Apr-2011
S0502 GIST, Imatinib +/- Bevacizumab SWOG 15-APR-08 5 2 572 .4 > 15 Yrs
GU I-II S0717 RCC, Adv, Bev + MEDI-522 SWOG 15-JUN-08 3 0 142 .0 > 15 Yrs
II S0353 Blad, sup TCC, Gemzar, Ph II SWOG 15-NOV-06 22 20 45 1.2 Jul-2010
III MDA3410 Consolidation chemo MDACC 08-MAY-02 20 .0
C90202 Pros,Bone mets,Zoledronic aci CALGB 15-JAN-04 33 .3
d
R0521 AS+RT vs AS+RT+Chemo RTOG 22-DEC-05 10 .8
R0415 Hypofrac v Conv 3D-CRG/IMRT RTOG 24-APR-06 1 .2
E2805 Renal, Adj Sunitib v Sorafinib ECOG 08-MAY-06 323 13.5
E3805 CHAARTED ECOG 08-AUG-06 2 .2
S0421 Pros, Adv, taxotere/atrasentan SWOG 21-AUG-06 25 288 930 28.5 Aug-2010
R0524 Pac + Trastuzumab vs Pac alone RTOG 08-DEC-06 3 .2
C90203 Pros, surgery +/- neoadj chem CALGB 22-DEC-06 16 2.2
o
S0337 Blad, Instill Gem vs Water SWOG 15-JUL-07 14 17 340 2.2 Mar-2021
PR11 Pros,local,Watch vs Active Tx NCIC 15-JUL-07 14 3 .3
E2804 BeST Trial ECOG 21-MAR-08 1 .2
LEUK BIOL S9007 Cytogen. Studies in Leuk. Pts. SWOG 15-JUL-91 206 3070 18.3
S9910 Leuk Central Lab/Tissue Repos SWOG 15-APR-99 113 1024 17.7
II S0333 Non-L3 ALL, Double Induction SWOG 15-APR-05 41 71 78 2.2 Jan-2009
S0605 AML, del5q, Age 60+, Revlimid SWOG 15-JUN-06 27 27 40 .8 Jan-2010
E1905 MDS/CMMoL/AML-TLD,Aza+/-MS-275 ECOG 01-OCT-06 24 17 123 .5
S0535 APL,High Risk, ATRA/arsenic/GO SWOG 15-NOV-07 10 0 70 .0 > 15 Yrs
C10403 ALL <30 yrs-Ped,Chemo. Regime CALGB 15-JAN-08 8 1 300 .2
n
II-III S0325 CML-CP, Dasatinib/Imatinib SWOG 15-AUG-04 49 353 400 10.0 Feb-2009
III S0106 AML, Mylotarg/Ara-C/Daunomycin SWOG 15-MAY-04 52 452 684 17.3 Nov-2009
S0521 APL,Low/Int Risk, Maint vs Obs SWOG 01-JUN-07 16 18 500 1.8 > 15 Yrs
C10501 CLL, Early Intervention vs Ob CALGB 22-JAN-08 0 .0
s
LUNG BIOL S9925 Lung, Biol, Tissue Repository SWOG 01-SEP-00 97 2245 4.0
I S0429 NSCL,PoorRisk,Stg III,Chemo/RT SWOG 01-APR-06 30 13 60 .5 Jul-2016
I-II S0533 NSCLC, CDDP/VP-16/RT+/- BCV SWOG 15-JUN-06 27 21 182 1.5 Sep-2017
II S0635 Bac, Stg IIIB/IV Bev + OSI-774 SWOG 15-JUL-07 14 16 88 1.5 Sep-2012
S0636 Adeno,IIIB/IV,Nsmk,Bev+OSI-774 SWOG 15-JUL-07 14 26 88 2.8 Jul-2010
III E5597 NSCLC,Stage I,Blinded Selenium ECOG 01-DEC-00 94 249 4.5
E1505 Stg IB-IIIA chemo +/- Bev ECOG 22-JUN-07 40 4.0
C140503 NSCL, Lobect v Sublobar rese CALGB 09-JUL-07 2 .3
ct
C30610 SCLC, Thoracic RT CALGB 21-MAR-08 3 .5
OTHER S0424 Molecular Epidemiology NSCLC SWOG 01-OCT-05 36 862 720 2.5 Feb-2004
LYMPH BIOL S8819 Lymphoma Immunophenotyping SWOG 15-FEB-89 235 445 .2
S8947 Lymphoma Serum Repository SWOG 15-APR-90 221 843 6.0
S9245 Relapsed Lymph Tissue Submis SWOG 15-MAR-93 186 31 .0
II S0313 NHL, CHOP + RT + R-Zevalin SWOG 01-FEB-04 56 44 60 .7 Sep-2010
S0350 NHL, PEGS, Phase II SWOG 15-SEP-05 36 11 50 .3 Jun-2018
S0410 HD, Rel, Tandem Auto PBSCT SWOG 15-OCT-05 35 74 85 3.3 Jan-2009
S0433 NHL, Adv, CHOP-R + I-131 SWOG 01-NOV-05 35 41 80 1.8 Jul-2010
S0520 NHL, Relapsed, PXD101, Ph II SWOG 01-JAN-06 33 18 40 .8 Dec-2010
III C50303 R-CHOP v EPOCH-R CALGB 15-SEP-06 14 .3
CTN0401 NHL, ASCT + R/BEAM vs. B/BEA BMT CTN 15-FEB-07 19 4 224 .3
M
MELAN II S0512 Melan,Adv,Uveal,BAY-43+Chemo SWOG 15-MAR-06 25 45 Mar-2008 Temp Close
S0438 Melan,Adv,BAY43+CCI779/R115777 SWOG 01-AUG-07 14 27 120 4.5 Jun-2010
III E1697 Melan, HDIFN vs Observation ECOG 15-OCT-02 100 1406 1.8
MMYEL BIOL S0120 Asympt Monoclonal Gammopathies SWOG 01-JUN-02 76 176 200 4.5 Mar-2009
S0309 MMYEL Specimen Repository SWOG 15-NOV-03 58 178 1.2
II S0115 Mel+PBSCT for High Risk MM+ALA SWOG 01-JAN-04 57 85 100 1.7 Jun-2009
S0629 WM, Obs, Ind, Mel+PBSCT, BEAM SWOG 15-SEP-08 0 0 50
III S0777 MM, Len Dex +/- Bortezomib SWOG 01-APR-08 6 8 440 1.3 > 15 Yrs
SWOG StatCtr Home Page